- Home
- SVRA vs CGEM Comparison
SVRA vs CGEM Comparison
Compare SVRA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- CGEM
- Stock Information
- Founded
- SVRA 2007
- CGEM 2016
- Country
- SVRA United States
- CGEM United States
- Employees
- SVRA N/A
- CGEM N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- CGEM Health Care
- Exchange
- SVRA Nasdaq
- CGEM Nasdaq
- Market Cap
- SVRA 528.3M
- CGEM 530.0M
- IPO Year
- SVRA N/A
- CGEM 2021
- Fundamental
- Price
- SVRA $2.21
- CGEM $7.81
- Analyst Decision
- SVRA Buy
- CGEM Strong Buy
- Analyst Count
- SVRA 5
- CGEM 5
- Target Price
- SVRA $5.60
- CGEM $30.00
- AVG Volume (30 Days)
- SVRA 1.2M
- CGEM 367.2K
- Earning Date
- SVRA 08-11-2025
- CGEM 08-07-2025
- Dividend Yield
- SVRA N/A
- CGEM N/A
- EPS Growth
- SVRA N/A
- CGEM N/A
- EPS
- SVRA N/A
- CGEM N/A
- Revenue
- SVRA N/A
- CGEM N/A
- Revenue This Year
- SVRA N/A
- CGEM N/A
- Revenue Next Year
- SVRA N/A
- CGEM N/A
- P/E Ratio
- SVRA N/A
- CGEM N/A
- Revenue Growth
- SVRA N/A
- CGEM N/A
- 52 Week Low
- SVRA $1.89
- CGEM $6.85
- 52 Week High
- SVRA $5.11
- CGEM $21.01
- Technical
- Relative Strength Index (RSI)
- SVRA 41.30
- CGEM 44.53
- Support Level
- SVRA $1.98
- CGEM $7.26
- Resistance Level
- SVRA $2.29
- CGEM $8.05
- Average True Range (ATR)
- SVRA 0.14
- CGEM 0.44
- MACD
- SVRA 0.02
- CGEM -0.07
- Stochastic Oscillator
- SVRA 42.19
- CGEM 32.55
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.